Edwards Lifesciences Co. (NYSE:EW) Shares Bought by Quantinno Capital Management LP

Quantinno Capital Management LP boosted its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 203.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 161,236 shares of the medical research company's stock after acquiring an additional 108,053 shares during the period. Quantinno Capital Management LP's holdings in Edwards Lifesciences were worth $11,936,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Crowley Wealth Management Inc. acquired a new position in Edwards Lifesciences during the 4th quarter worth approximately $26,000. Millstone Evans Group LLC acquired a new position in Edwards Lifesciences during the 4th quarter worth approximately $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Edwards Lifesciences during the 4th quarter worth approximately $30,000. Roble Belko & Company Inc acquired a new position in Edwards Lifesciences during the 4th quarter worth approximately $46,000. Finally, Catalyst Capital Advisors LLC acquired a new position in Edwards Lifesciences during the 4th quarter worth approximately $54,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Stock Up 2.0%

Shares of Edwards Lifesciences stock opened at $77.04 on Thursday. The company has a market cap of $45.19 billion, a P/E ratio of 11.05, a PEG ratio of 4.82 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $95.25. The firm has a fifty day moving average of $71.73 and a two-hundred day moving average of $71.62.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. The company had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Edwards Lifesciences's quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.66 EPS. On average, analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insider Activity

In other news, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the transaction, the director now owns 60,372 shares in the company, valued at $4,613,628.24. This trade represents a 8.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $70.78, for a total transaction of $796,275.00. Following the completion of the transaction, the chief financial officer now owns 30,387 shares of the company's stock, valued at $2,150,791.86. This represents a 27.02% decrease in their position. The disclosure for this sale can be found here. Insiders sold 71,931 shares of company stock worth $5,148,028 in the last 90 days. 1.29% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

EW has been the subject of several analyst reports. Truist Financial lowered their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a report on Friday, April 11th. StockNews.com upgraded shares of Edwards Lifesciences from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Morgan Stanley upped their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a report on Wednesday, February 12th. Robert W. Baird upped their target price on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a report on Thursday, April 24th. Finally, Barclays upped their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating and twelve have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $79.60.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.